Date of Award
Master of Science (MS)
The utility of genes PTEN and FAS as prognostic markers for the identification of early and/or aggressive prostatic adenocarcinomas is seemingly validated in the study results we obtained using fluorescence in-situ hybridization (FISH) of archived paraffin embedded surgical prostate core biopsy samples obtained from two CLIA and CAP licensed anatomical pathology labs (Bostwick Laboratories, Uniondale, NV and GoPath Laboratories, Buffalo Grove, IL). From early benign subsets of sample cases to aggressive extracapsular invasive tumors, the presence of random deletions evolves into clonal populations of co-deletion of both genes at question. We identify independent research that demonstrates the ability of these two genes to work together in a pathway of rapid cell division and then (or sometimes concomitant) evasion of said neoplastic tumor cell lines from innate cell mediated immunity. Sample size limitations limits predictive values in our study, however this research adds credence to personal anecdotal observation I have made in the past in the capacity of FISH clinical operations and validation management and personal “bench work.” Further, since the onset of our research, using a completely different modality, scientists have studied the same markers together and reached the similar if not the same conclusions.
Coulter, Brendan J. and Harries, Phillip, "THE CLINICAL UTILITY OF CONCOMITANT PTEN AND FAS DELETION AS AN EARLY INDICATOR FOR PROSTATE ADENOCARCINOMA SUBTYPES THAT LEAD TO EXTRACAPSULAR METASTASIS" (2016). Electronic Theses & Dissertations. 237.